Tel Aviv University

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Teva Pharmaceutical Industries Limited

Brainstorm Cell Therapeutics Ltd.

Other

Yeda Research and Develpment & Co. Ltd

Ceva D.s.p. Ltd.

Brainstorm Ceil Therapeutics Ltd.

Parthuseeva Ltd.

Yissum

Eldad Melamed

Daniel Offen

Merav Bahat-Stromza

Daphne Atlas

Avinoam Kadouri

Ofer Sadan

Avihay Bar-Ilan

Alexander Veinberg

Isaac Milman

Nirit Lev

Michal Dadon-Nachum

Tali Ben-Zur

David Yaffe

Ilan Ziv

Ruth Levy

Sasson Cohen

Sandu Pitaru

Roni M Sadeh

Yaron M Sadeh

Javier Ganz

Ruth Djaldetti

Dafna Atlas

Nava Shterman

Sela Yoram

Daniel Ofen

Erez Barniv

An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.

Mesenchymal stem cells for the treatment of CNS diseases

An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.

Isolated cells and populations comprising same for the treatment of CNS diseases

An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.

Genetically modified muscle cells which express neurotrophic factors

The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.

Stem cell-derived neural cells for cell therapy in neurological disorders

Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.

Peptides for the treatment of oxidative stress related disorders

A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises:

Peptides for the regulation of neurotransmitter sequestration and release

A system and method for controlling video compression quantization comprising generating a quantizer scale offset based on diagonal frequencies of luminance components of a data block samples, luminance intensity of the samples and motion activity of the data block, adjusting a first quantizer scale using the quantizer scale offset to receive a second quantizer scale and quantizing the data block using the second quantizer scale.

Method and system for real-time adaptive quantization control

Growing community of inventors

Tel Aviv, Israel

Eldad Melamed